Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by gebremeskelon Jan 20, 2025 7:53pm
55 Views
Post# 36412554

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TODAY’S NUMBERS

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TODAY’S NUMBERSThanks BlueJays9293 for the interesting and informative reply.

BlueJays9293 wrote: I think regulations would make it really hard for Spectral to sit on that kind of information for very long without disclosing it to shareholders.  That's not to say that that kind of deal couldn't happen at any moment in the future, but as of now it's fair to assume that a deal hasn't been agreed to yet. 

Have preliminary discussions happened for CG to get a ball park amount that Spectral is seeking?  That's more of a grey area in regulations but generally speaking, the moment CG makes an offer to Spectral, the disclosure clock starts ticking, and it only allows for days before it must be disclosed to shareholders.  "On-going" negotiations also allows for flexibility on having to disclose but even those must eventually be disclosed.

In my mind, the sweet spot for CG to takeover Spectral, is after the final patient has been enrolled, but before the official release of top line numbers.  This sweet spot allows for the Tigris data to be officially locked in, but, before the numbers are released to the world and other interested parties getting wind of it.




<< Previous
Bullboard Posts
Next >>